NeuroSense's PrimeC Advances Toward Phase 3 Trials NeuroSense Therapeutics' PrimeC, a drug targeting ALS, has shown significant efficacy in Phase 2b trials, achieving a 29% improvement over placebo in slowing disease progression. With FDA and EMA 'Orphan Drug' status, the company is preparing for Phase 3 trials, offering new hope for ALS patients worldwide.1